Summary of recommended regimens for treatment-naïve people with HCV

Table 3. Recommended treatment protocols for treatment-naive people with hepatitis C virus (HCV) infection and compensated liver disease, including people with HCV–HIV coinfection

 

 

Treatment duration

Regimen

HCV genotype

No cirrhosis

Cirrhosis

Sofosbuvir 400 mg, orally, daily
+
Velpatasvir 100 mg, orally, daily

1, 2, 3, 4, 5, 6

12 weeks

12 weeks*

Glecaprevir 300 mg, orally, daily
+
Pibrentasvir 120 mg, orally, daily

1, 2, 3, 4, 5, 6

8 weeks

12 weeks

Elbasvir 50 mg, orally, daily
+
Grazoprevir 100 mg, orally, daily

1, 4

12 weeks

12 weeks

Sofosbuvir 400 mg, orally, daily
+
Ledipasvir 90 mg, orally, daily

1

8 or 12 weeks

12 weeks

HIV = human immunodeficiency virus.

* Addition of ribavirin may be considered for patients with genotype 3 HCV and compensated cirrhosis. Ribavirin dosing is weight-based; recommended dose is 1000 mg for people weighing < 75 kg and 1200 mg for people weighing ≥ 75 kg.

† 8 weeks may be considered if HCV RNA level is < 6 × 106 IU/mL in people with no cirrhosis who are treatment-naive.

Notes: Sofosbuvir is not recommended for patients with an estimated glomerular filtration rate < 30 mL/min/1.73 m2. Dose reduction or dose interruption of direct-acting antiviral therapy is not recommended. Dose reduction of ribavirin for the management of symptomatic anaemia according to the product information is appropriate and will not reduce the likelihood of SVR. The recommended treatment regimens differ in the setting of decompensated liver disease (Child–Pugh score ≥ B7).